Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice

Shanthadevi Udayappan, Louise Manneras-Holm, Alice Chaplin-Scott, Clara Belzer, Hilde Herrema, Geesje M Dallinga-Thie, Erik S G Stroes, Albert K Groen, Harry J Flint, Fredrik Backhed, Willem M de Vos, Max Nieuwdorp, Sylvia Helen Duncan

Research output: Contribution to journalArticle

26 Citations (Scopus)
3 Downloads (Pure)

Abstract

An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

Original languageEnglish
Article number16009
JournalNPJ biofilms and microbiomes
Volume2
DOIs
Publication statusPublished - 6 Jul 2016

Fingerprint

Eubacterium
Insulin Resistance
Butyrates
Hot Temperature
Glucose Clamp Technique
Anaerobic Bacteria
Therapeutics
Bile Acids and Salts
Glycerol
Type 2 Diabetes Mellitus
Energy Metabolism
Insulin
Phenotype
Gastrointestinal Microbiome

Keywords

  • Journal Article

Cite this

Udayappan, S., Manneras-Holm, L., Chaplin-Scott, A., Belzer, C., Herrema, H., Dallinga-Thie, G. M., ... Duncan, S. H. (2016). Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ biofilms and microbiomes, 2, [16009]. https://doi.org/10.1038/npjbiofilms.2016.9

Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. / Udayappan, Shanthadevi; Manneras-Holm, Louise; Chaplin-Scott, Alice; Belzer, Clara; Herrema, Hilde; Dallinga-Thie, Geesje M; Stroes, Erik S G; Groen, Albert K; Flint, Harry J; Backhed, Fredrik; de Vos, Willem M; Nieuwdorp, Max; Duncan, Sylvia Helen.

In: NPJ biofilms and microbiomes, Vol. 2, 16009, 06.07.2016.

Research output: Contribution to journalArticle

Udayappan, S, Manneras-Holm, L, Chaplin-Scott, A, Belzer, C, Herrema, H, Dallinga-Thie, GM, Stroes, ESG, Groen, AK, Flint, HJ, Backhed, F, de Vos, WM, Nieuwdorp, M & Duncan, SH 2016, 'Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice', NPJ biofilms and microbiomes, vol. 2, 16009. https://doi.org/10.1038/npjbiofilms.2016.9
Udayappan S, Manneras-Holm L, Chaplin-Scott A, Belzer C, Herrema H, Dallinga-Thie GM et al. Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ biofilms and microbiomes. 2016 Jul 6;2. 16009. https://doi.org/10.1038/npjbiofilms.2016.9
Udayappan, Shanthadevi ; Manneras-Holm, Louise ; Chaplin-Scott, Alice ; Belzer, Clara ; Herrema, Hilde ; Dallinga-Thie, Geesje M ; Stroes, Erik S G ; Groen, Albert K ; Flint, Harry J ; Backhed, Fredrik ; de Vos, Willem M ; Nieuwdorp, Max ; Duncan, Sylvia Helen. / Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. In: NPJ biofilms and microbiomes. 2016 ; Vol. 2.
@article{1a07cac01c1a4c53866bbcdb5ff73bb2,
title = "Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice",
abstract = "An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.",
keywords = "Journal Article",
author = "Shanthadevi Udayappan and Louise Manneras-Holm and Alice Chaplin-Scott and Clara Belzer and Hilde Herrema and Dallinga-Thie, {Geesje M} and Stroes, {Erik S G} and Groen, {Albert K} and Flint, {Harry J} and Fredrik Backhed and {de Vos}, {Willem M} and Max Nieuwdorp and Duncan, {Sylvia Helen}",
note = "F.B. is supported by Swedish Research Council, Swedish Diabetes Foundation, Swedish Heart Lung Foundation, Swedish Foundation for Strategic Research, Knut and Alice Wallenberg foundation, G{\"o}ran Gustafsson Foundation, Ingbritt and Arne Lundberg’s foundation, Swedish Heart Lung Foundation, Torsten S{\"o}derberg’s Foundation, Ragnar S{\"o}derberg’s Foundation, NovoNordisk Foundation, AFA insurances, and LUA-ALF grants from V{\"a}stra G{\"o}talandsregionen and Stockholm County Council. F.B. is a recipient of ERC Consolidator Grant (European Research Council, Consolidator grant 615362—METABASE). W.M.d.V. is supported by the Finland Academy of Sciences (grants 137389, 141140 and 1272870 ), the Netherlands Organization for Scientific Research (Spinoza Award and SIAM Gravity Grant 024.002.002) and the European Research Council (ERC Advanced Grant 250172 MicrobesInside). M.N. is supported by a ZONMW-VIDI grant 2013 (016.146.327).",
year = "2016",
month = "7",
day = "6",
doi = "10.1038/npjbiofilms.2016.9",
language = "English",
volume = "2",
journal = "NPJ biofilms and microbiomes",
issn = "2055-5008",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice

AU - Udayappan, Shanthadevi

AU - Manneras-Holm, Louise

AU - Chaplin-Scott, Alice

AU - Belzer, Clara

AU - Herrema, Hilde

AU - Dallinga-Thie, Geesje M

AU - Stroes, Erik S G

AU - Groen, Albert K

AU - Flint, Harry J

AU - Backhed, Fredrik

AU - de Vos, Willem M

AU - Nieuwdorp, Max

AU - Duncan, Sylvia Helen

N1 - F.B. is supported by Swedish Research Council, Swedish Diabetes Foundation, Swedish Heart Lung Foundation, Swedish Foundation for Strategic Research, Knut and Alice Wallenberg foundation, Göran Gustafsson Foundation, Ingbritt and Arne Lundberg’s foundation, Swedish Heart Lung Foundation, Torsten Söderberg’s Foundation, Ragnar Söderberg’s Foundation, NovoNordisk Foundation, AFA insurances, and LUA-ALF grants from Västra Götalandsregionen and Stockholm County Council. F.B. is a recipient of ERC Consolidator Grant (European Research Council, Consolidator grant 615362—METABASE). W.M.d.V. is supported by the Finland Academy of Sciences (grants 137389, 141140 and 1272870 ), the Netherlands Organization for Scientific Research (Spinoza Award and SIAM Gravity Grant 024.002.002) and the European Research Council (ERC Advanced Grant 250172 MicrobesInside). M.N. is supported by a ZONMW-VIDI grant 2013 (016.146.327).

PY - 2016/7/6

Y1 - 2016/7/6

N2 - An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

AB - An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

KW - Journal Article

U2 - 10.1038/npjbiofilms.2016.9

DO - 10.1038/npjbiofilms.2016.9

M3 - Article

VL - 2

JO - NPJ biofilms and microbiomes

JF - NPJ biofilms and microbiomes

SN - 2055-5008

M1 - 16009

ER -